Posted by Michael Wonder on 17 Jan 2018
Pfizer asked to submit CDF proposal for Xalkori
17 January 2018 - Pfizer’s Xalkori has been turned away by NICE to treat ROS1-positive advanced non-small cell lung cancer.
Cost effectiveness estimates for the drug when used in this setting are higher than what would normally be considered value for money for the NHS, being “well over £50,000 per QALY gained and highly uncertain”, the Institute concluded.
However, there may be a reprieve for Xalkori (crizotinib) yet as the company has been asked to submit a proposal for its inclusion in the Cancer Drugs Fund instead, for treatment-naïve patients.
